#1 Clinical Trials Search in Europe

Mps-103

This article summarizes several clinical trials investigating the use of MPS-103, a component of the OSE2101 (Tedopi) cancer vaccine, in treating various advanced cancers. OSE2101 is being studied alone and in combination with other therapies for non-small cell lung cancer, ovarian cancer, and pancreatic cancer. The trials aim to evaluate the safety and efficacy of OSE2101 in improving outcomes for patients with these difficult-to-treat advanced cancers.

Table of Contents

What is MPS-103?

MPS-103 is one of the active substances in an investigational cancer vaccine called TEDOPI[1]. TEDOPI is being developed by OSE Immunotherapeutics as a potential new treatment for certain types of cancer. It contains 10 synthetically manufactured peptides (small protein fragments), including MPS-103[2].

How Does MPS-103 Work?

As part of the TEDOPI vaccine, MPS-103 is designed to stimulate the immune system to recognize and attack cancer cells. The vaccine works by presenting specific protein fragments that are found on cancer cells to the immune system. This helps train the immune system to identify these cancer-associated proteins as foreign and mount an attack against cells displaying them[1].

What Conditions is MPS-103 Being Studied For?

TEDOPI, which contains MPS-103, is currently being investigated for the treatment of several types of cancer, including:

  • Non-small cell lung cancer (NSCLC): This is a type of lung cancer that is being studied in patients whose cancer has progressed after previous immunotherapy treatment[1].
  • Ovarian cancer: TEDOPI is being evaluated as a maintenance treatment for patients with recurrent ovarian cancer that is sensitive to platinum-based chemotherapy[3].
  • Pancreatic cancer: The vaccine is being studied in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma[4].

Current Clinical Trials

Several clinical trials are currently underway to evaluate the safety and effectiveness of TEDOPI (containing MPS-103) in different cancer types:

  • ARTEMIA study: This is a phase 3 trial comparing TEDOPI to docetaxel (a chemotherapy drug) in patients with advanced non-small cell lung cancer who have developed resistance to previous immunotherapy[1].
  • TEDOVA study: A phase 2 trial evaluating TEDOPI alone or in combination with pembrolizumab (another immunotherapy drug) as a maintenance treatment for patients with recurrent ovarian cancer[3].
  • TEDOPAM study: A phase 2 trial investigating TEDOPI in combination with chemotherapy for patients with advanced pancreatic cancer[4].

Potential Benefits and Side Effects

As TEDOPI (including MPS-103) is still in clinical trials, its full benefits and risks are not yet fully known. However, researchers hope that it may provide a new treatment option for patients with certain types of cancer, particularly those who have not responded well to other treatments[1][3][4].

Potential benefits being studied include:

  • Improved overall survival
  • Longer progression-free survival (time without cancer growing or spreading)
  • Better quality of life compared to some existing treatments

As with any medical treatment, there may be side effects. Common side effects of cancer vaccines can include injection site reactions, fatigue, and flu-like symptoms. More serious side effects are possible but less common. The ongoing clinical trials are carefully monitoring patients for any adverse effects[1][3][4].

It’s important to note that as an investigational treatment, TEDOPI (containing MPS-103) is not yet approved for general use. Patients interested in this treatment should speak with their healthcare provider about the possibility of participating in clinical trials.

Trial Name Cancer Type Treatment Primary Endpoint Key Eligibility Criteria
ARTEMIA Metastatic NSCLC OSE2101 vs docetaxel Overall Survival HLA-A2 positive, progressed after immunotherapy
OSE-279 Combination Advanced solid tumors, lymphomas, NSCLC OSE-279 +/- OSE2101 Safety, MTD, RP2D, ORR HLA-A2 positive for some cohorts
TEDOVA Recurrent ovarian cancer OSE2101 +/- pembrolizumab vs best supportive care Progression-free survival HLA-A2 positive, platinum-sensitive
TEDOPAM Advanced pancreatic cancer OSE2101 + FOLFIRI vs FOLFIRI alone Overall survival at 12 months HLA-A2 positive, stable after FOLFIRINOX

FAQ

  • What is MPS-103? MPS-103 is one of the active substances in OSE2101 (Tedopi), an experimental cancer vaccine being studied to treat various advanced cancers. It is part of a combination of synthetic peptides designed to stimulate the immune system to target cancer cells.
  • What types of cancer is OSE2101 being studied for? Based on the clinical trials summarized, OSE2101 is being investigated for advanced non-small cell lung cancer, recurrent ovarian cancer, and locally advanced or metastatic pancreatic cancer.
  • How is OSE2101 administered? OSE2101 is administered as a subcutaneous injection or emulsion for injection. The exact dosing schedule varies between trials but typically involves regular injections over several months.
  • What are some of the main outcomes being measured in these trials? Key outcomes being evaluated include overall survival, progression-free survival, objective response rate, safety/tolerability, and quality of life measures. Some trials are also looking at biomarkers that may predict response to treatment.
  • Is OSE2101 being studied alone or in combination with other treatments? OSE2101 is being studied both as a monotherapy and in combination with other treatments like chemotherapy (FOLFIRI) and immunotherapy (pembrolizumab) in different trials, depending on the cancer type and treatment setting.

Ongoing Clinical Trials on Mps-103

  • Study on Cemiplimab and OSE2101 for Maintenance Therapy in Patients with ctDNA Positive Non-Small Cell Lung Cancer (NSCLC)

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

  • Study on Tedopi and Nivolumab for Patients with Advanced Non-Small Cell Lung Cancer After Initial Treatment

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Italy Spain

  • Study Comparing OSE2101 and Docetaxel for Patients with Metastatic Non-Small Cell Lung Cancer After Immunotherapy Resistance

    Recruiting

    3 1 1 1
    Investigated drugs:
    Belgium France Germany Greece Hungary Italy +5

  • Study of OSE-279 and OSE2101 Drug Combination for Patients with Advanced Solid Tumors, Lymphomas, or Metastatic Non-Small Cell Lung Cancer

    Recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France Spain

  • Study on Maintenance Therapy with OSE2101 and FOLFIRI for Patients with Advanced Pancreatic Cancer After Initial FOLFIRINOX Treatment

    Not yet recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study of OSE2101 vaccine alone or with pembrolizumab as maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer after chemotherapy

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France Germany

Glossary

  • OSE2101 (Tedopi): An experimental cancer vaccine containing multiple synthetic peptides, including MPS-103, designed to stimulate the immune system to target cancer cells.
  • HLA-A2: A specific type of human leukocyte antigen (HLA) protein. Patients must be HLA-A2 positive to be eligible for most of the OSE2101 trials.
  • NSCLC: Non-small cell lung cancer, a common type of lung cancer being studied in some of the OSE2101 trials.
  • Progression-free survival (PFS): The length of time during and after treatment that a patient lives without the cancer progressing or getting worse.
  • Overall survival (OS): The length of time from the start of treatment or diagnosis that patients are still alive.
  • RECIST: Response Evaluation Criteria in Solid Tumors, a standard way to measure how well a cancer patient responds to treatment.
  • Objective response rate (ORR): The proportion of patients whose cancer shrinks or disappears after treatment.
  • FOLFIRINOX: A combination chemotherapy regimen used to treat pancreatic cancer, consisting of folinic acid, fluorouracil, irinotecan, and oxaliplatin.
  • Sarcopenia: Age-related loss of muscle mass and function, which may affect how patients respond to cancer treatments.
  • Immune-related adverse events (imAEs): Side effects related to the immune system that can occur with cancer immunotherapies like OSE2101.

References

  1. http://clinicaltrials.eu/trial/study-comparing-ose2101-and-docetaxel-for-patients-with-metastatic-non-small-cell-lung-cancer-after-immunotherapy-resistance/
  2. http://clinicaltrials.eu/trial/study-of-ose-279-and-ose2101-drug-combination-for-patients-with-advanced-solid-tumors-lymphomas-or-metastatic-non-small-cell-lung-cancer/
  3. http://clinicaltrials.eu/trial/study-of-maintenance-treatments-with-ose2101-and-pembrolizumab-for-patients-with-recurrent-ovarian-cancer-after-platinum-based-chemotherapy/
  4. http://clinicaltrials.eu/trial/study-on-maintenance-therapy-with-ose2101-and-folfiri-for-patients-with-advanced-pancreatic-cancer-after-initial-folfirinox-treatment/